Hermann Luebbert: Well, that’s still hard to tell. It’s also a question of the amount of money that we can invest into this project. We could certainly speed it up if we have the funds available for that, so that is still at least one or two years out.
Jonathan Aschoff: And you would expect the portable to eclipse the two currently available lamps, right? Or is the surface area not as big as the XL?
Hermann Luebbert: It’s not quite as big, but it’s also much bigger than with the current with the small lamp, so it’s somewhere two-thirds in between towards the XL.
Jonathan Aschoff: Okay. Thanks. It sounds like that’s moving along nicely. Thank you.
Operator: The next question comes from Bruce Jackson with The Benchmark Company. Please go ahead.
Bruce Jackson: Hi. Good morning, and thank you for taking my questions. I wanted to start off with XEPI. So is the new contract manufacturer qualified yet?
Hermann Luebbert: The new manufacturer is qualified, so the pilot batches have been done, and the manufacturer has been – the pilot batches have been submitted to the FDA and approved. And so what comes next is the qualification batches, and they will be produced this month. And with three months stability on these batches, we can actually start selling them.
Bruce Jackson: And that was going to be my next question about XEPI, so we said you were contemplating a relaunch. Do you have any more specificity on are you going to relaunch the product and when during 2024 would you be doing that, if you do it?
Hermann Luebbert: That hasn’t been fully determined yet, how to like best use of the product in our portfolio. And there are many options that we are currently looking at or several options that we are looking at. So this will be decided relatively shortly in preparation for the ability to launch.
Bruce Jackson: Okay. Great. And then a quick question about the 3-tube data. Has that been submitted to the FDA yet?
Hermann Luebbert: Not yet. It will be submitted in the course of this month.
Bruce Jackson: Okay. Great. And then last question about the price increase and then the 25% – or better guidance for the year. So how much of the revenue gap pulled forward is due to the price increase do you think in the third quarter?
Hermann Luebbert: That’s – it’s always difficult to say how much was pulled forward. When we look at our historical experience with price increases and buy-in into that, then it’s almost a couple of thousand tubes. However, given the fact that Q4 is our strongest quarter, we don’t expect that Q4 now will be a bad quarter because everybody bought everything in Q3, I assume that this is where your question is heading at. So we still expect a significant increase in the fourth quarter, but not anything like the 100% we saw in Q3.
Bruce Jackson: Got it. So still up year-over-year and sequentially over the third quarter.
Hermann Luebbert: Yes.
Bruce Jackson: Okay, great. All right. Thank you very much.
Hermann Luebbert: Thank you, Bruce.
Operator: This concludes our question-and-answer session. I would like to turn the conference back over to Hermann Luebbert for any closing remarks.
Hermann Luebbert: Thank you all for the questions, to analysts, and thanks to everybody again for listening in. To summarize, I’m very encouraged for the strong sales growth we delivered this past quarter and by the increase in the number of Ameluz tube orders and RhodoLED lamp installations. As I mentioned, we remain on track to grow the revenues at least 25% this year, driven primarily by Ameluz sales and a maturing commercial organization. So we look forward to speaking with you again when we report our fourth quarter and full year 2024 results. Thank you, and have a nice day.
Fred Leffler: The conference has now concluded. Thank you for attending today’s presentation. You may now disconnect.
